Search This Blog

Wednesday, December 18, 2019

Mirum Completes Successful Pre-NDA Meeting with FDA for Maralixibat

FDA Requested Change from Type-C Meeting to pre-NDA Meeting
Company Plans to Initiate Rolling NDA Submission in Third Quarter 2020
Rare Pediatric Disease Designation Granted for Maralixibat for Alagille Syndrome
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)